Bromelain |
Catalog No.GC62536 |
La bromélaÏne est un médicament anti-inflammatoire dérivé de la tige d'ananas qui agit par la régulation À la baisse du kininogène plasmatique, l'inhibition de l'expression de la prostaglandine E2, la dégradation des récepteurs avancés du produit final de glycation et la régulation des biomarqueurs angiogéniques ainsi que l'action antioxydante en amont dans la voie COX. .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9001-00-7
Sample solution is provided at 25 µL, 10mM.
Bromelain is an anti-inflammatory drug derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway[1]. Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death[2].
Bromelain (40 mg/kg; intraperitoneal injection; daily; for 7 days; male Sprague-Dawley rats) pretreatment reduces the motor dysfunction in the parkinsonian rat model of parkinson’s disease (PD). 6-OHDA injection resulted in marked motor impairment which is prevented by pretreatment with Bromelain prior to the lesion[1].
[1]. Adu TS, et al. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism. Metab Brain Dis. 2019 Jul 22.
[2]. Pavan R, et al. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203.
Average Rating: 5
(Based on Reviews and 3 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *